Tovorafenib (1) – Ojemda®
Malignant glioma, low-grade with a BRAF fusion or rearrangement or a BRAF V600 mutation, following at least one prior line of treatment, ≥ 6 months
Characteristics
| Start date | 15.05.2026 |
|---|---|
| Resolution | 05.11.2026 – active procedure |
| INN | Tovorafenib |
| Brand name | Ojemda® |
| Pharm. company | Ipsen Pharma GmbH |
| G-BA Procedure ID | D-1319 |
| Therapeutic area | Oncological diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions